Loading...
XKRX
102460
Market cap120mUSD
Jul 10, Last price  
10,070.00KRW
1D
2.13%
1Q
1.72%
Jan 2017
-54.11%
IPO
-4.62%
Name

Reyon Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XKRX:102460 chart
P/E
—
P/S
1.27
EPS
—
Div Yield, %
—
Shrs. gr., 5y
1.77%
Rev. gr., 5y
2.33%
Revenues
145.93b
-1.60%
55,906,318,00072,932,904,00095,187,341,000120,827,191,000124,350,931,480114,334,848,060109,693,359,770112,112,066,710114,507,234,540121,847,219,920126,253,125,650122,990,417,380131,557,875,000130,034,153,000142,801,368,000154,038,839,000151,071,143,910148,299,674,000145,928,626,000
Net income
-29.83b
L
6,086,421,0008,065,547,00016,287,993,00019,981,933,00019,779,374,32016,990,558,94011,292,961,39011,593,285,51011,337,932,74010,701,369,00012,886,901,0001,342,892,9105,941,670,0003,844,427,0005,537,252,0007,433,682,0003,583,373,1204,151,240,000-29,825,512,000
CFO
1.23b
P
8,049,026,0005,985,742,0008,683,539,00018,191,445,00013,238,641,08022,070,046,340-51,792,71015,102,444,1709,663,900,5809,471,438,00016,763,965,00011,449,210,060-12,183,516,0004,599,407,00011,684,528,0008,729,174,0008,645,127,000-1,435,814,0001,229,024,000
Dividend
Dec 27, 2024150 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Operating both domestically in South Korea and across international markets, REYON Pharmaceutical Co., Ltd. specializes in the production and distribution of pharmaceutical products and active pharmaceutical ingredients (APIs). The company's diverse range of offerings addresses various therapeutic areas, including adrenal corticosteroids; angiotensin II receptor antagonists; anticholinergics; antiemetics; antihypertensives; anti-inflammatory enzymes; lipid-lowering, antirheumatic, and oral hypoglycemic agents; anti-peptic ulcer treatments; antispasmodics; benign prostatic hypertrophy therapies; cough and cold remedies; cardiac stimulants; genitourinary smooth muscle relaxants; hemostatics; immunosuppressants; rheumatoid arthritis medications; local anesthetics; migraine drugs; a variety of cardiovascular system drugs; medications for neuromuscular disorders; nootropics and neurotonics; non-steroidal anti-inflammatory drugs (NSAIDs); respiratory stimulants; skeletal muscle relaxants; and vasodilators. Established in 1955, REYON Pharmaceutical Co., Ltd. maintains its corporate headquarters in Seoul, South Korea.
URL
https://reyonpharm.co.kr/en/main/main.do
IPO date
Jun 10, 2010
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT